spec sheet8 rows
IBMX (3-isobutyl-1-methylxanthine) is a synthetic methylxanthine and nonselective phosphodiesterase inhibitor that also antagonizes adenosine receptors, widely used as a research reagent to raise intracellular cAMP and cGMP. It inhibits most cyclic-nucleotide phosphodiesterase families in the low-micromolar range while comparatively sparing PDE8 and PDE9, and it is a standard component of cell-differentiation cocktails for adipocytes and melanocytes as well as a common positive control in phosphodiesterase and adenosine-receptor pharmacology assays.
- Raises intracellular cAMP and cGMP by blocking their breakdown across most PDE families
- Standard positive control for phosphodiesterase inhibition in pharmacology assays
- Key component of adipocyte differentiation cocktails alongside dexamethasone and insulin
- Triggers melanogenesis in melanocyte cultures via cAMP-driven MITF signaling
- Antagonizes adenosine receptors, adding a caffeine-like disinhibitory tone
- Amplifies hormone- and forskolin-stimulated signaling in isolated tissue preparations
- Methylxanthine stimulant properties can raise heart rate and cause jitteriness
- Like caffeine, can lower seizure threshold at high exposure
Overview
IBMX is pretty much the reference-standard PDE inhibitor; if you have ever run a cAMP assay or cooked up an adipocyte differentiation cocktail, this is the xanthine doing the heavy lifting. The appeal is how clean the story is; it blocks the enzymes that chew up cAMP and cGMP and it knocks adenosine off its receptors, so cyclic-nucleotide signaling just climbs. It is essentially a lab tool rather than something you would take, and that deserves to be said plainly; there is no human dosing here, and the methylxanthine stimulant side plus cytotoxicity at high concentrations means it stays on the bench. As a mechanistic workhorse for understanding the whole caffeine, adenosine and PDE axis, though, it is hands down one of the most useful molecules on the shelf.
Mechanism
IBMX is a methylxanthine that works through two linked mechanisms. First, it nonselectively inhibits cyclic-nucleotide phosphodiesterases (PDEs; the enzymes that hydrolyze the second messengers and cGMP), so both messengers accumulate and downstream protein kinase A (PKA) and protein kinase G (PKG) signaling is amplified; it hits most PDE families in the low-micromolar range but is comparatively weak against PDE8 and PDE9. Second, it acts as a competitive (and weak inverse ) at P1 receptors, chiefly A1 and A2A, removing adenosine's inhibitory brake on adenylyl cyclase. The net effect is elevated intracellular cyclic nucleotides plus a caffeine-like disinhibition of cyclase activity, which is why it reliably drives cAMP-dependent processes like lipolysis, melanogenesis and smooth-muscle relaxation in cell and tissue models.
receptor fingerprint
Phosphodiesterase PDE1Inhibits
Phosphodiesterase PDE3Inhibits
Phosphodiesterase PDE4Inhibits
Phosphodiesterase PDE5Inhibits
A1 receptorAntagonizes
Phosphodiesterase PDE9Inhibits
Phosphodiesterase PDE8Inhibits
A2A receptorAntagonizes
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
IBMX is a laboratory reagent with no established human dosing or clinical safety profile. As a methylxanthine it shares caffeine-like stimulant effects such as raised heart rate, jitteriness and a lowered seizure threshold at high exposure. At the high micromolar concentrations used in vitro it can be cytotoxic and pro-apoptotic in some cell lines. Its nonselective action across PDE families and adenosine receptors makes it unsuitable as a targeted therapeutic. It is not scheduled but should be handled as a research chemical, not a supplement.
Subjective profileweighing the evidence above
A workhorse research reagent, not a consumer compound; hands down the standard nonselective PDE inhibitor for raising cAMP and cGMP in the lab, but with no human dosing and real stimulant and cytotoxicity caveats it belongs on the bench.
Resources
This entry is here for reference.
Research
- 2004first citedCrystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-…
- 2017most recentRelaxation of isolated guinea-pig trachea by apigenin, a constituent of celery, via inhibition…
- 1.Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding
- 2.Validation of a Na-shift binding assay for estimation of the intrinsic efficacy of ligands at the A2A adenosine receptor
- 3.Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis
- 4.CD36 level and trafficking are determinants of lipolysis in adipocytes
- 5.Relaxation of isolated guinea-pig trachea by apigenin, a constituent of celery, via inhibition of phosphodiesterase
- 6.Cyclic AMP efflux, via MRPs and A1 adenosine receptors, is critical for bovine sperm capacitation
6 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is IBMX used for?
Mostly as a research tool; it is a nonselective PDE inhibitor and adenosine antagonist used to raise cAMP and cGMP in cell and tissue experiments, and a standard ingredient in adipocyte and melanocyte differentiation media.
How does IBMX work?
It blocks phosphodiesterases so cAMP and cGMP are not degraded, and it antagonizes adenosine receptors; both actions push cyclic-nucleotide signaling upward.
Is IBMX well-researched?
Yes, hands down; it is one of the most cited PDE inhibitors in cell biology, with decades of use as a positive control and crystal-structure work mapping exactly how it sits in the PDE active site.
Is IBMX a stimulant like caffeine?
Chemically it is a close methylxanthine cousin and shares adenosine antagonism, so it carries caffeine-like stimulant tone; it is far more potent as a PDE inhibitor, though, and is used as a reagent rather than a beverage compound.
What are the main side effects?
It is not a consumer product, so there is no human safety profile; the concerns are stimulant effects, cytotoxicity at high concentrations, and hard-to-interpret nonselective signaling.
Adverse effects
- Methylxanthine stimulant properties can raise heart rate and cause jitteriness
- Like caffeine, can lower seizure threshold at high exposure
Notes and cautions
- Primarily a lab reagent, not a consumer supplement; no established human dosing
- High concentrations are cytotoxic and can trigger apoptosis in some cell lines
- Nonselective action makes clean interpretation of downstream effects difficult